Case Study: Regulatory Action Due to Integrity Breach in Stability Data
In the pharmaceutical industry, integrity breaches in stability testing can have catastrophic consequences—both from a regulatory and patient safety standpoint. This article explores a real-world case where the U.S. Food and Drug Administration (FDA) issued a warning letter following serious data integrity failures in a company’s stability program. We analyze what went wrong, how regulators…
Read More “Case Study: Regulatory Action Due to Integrity Breach in Stability Data” »